NSRX Nasus Pharma Ltd.

2.550USD-5.56%Mkt Cap: 29.87M USDP/E: —

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute…

Institutional holders10 on file

Key Statistics

Company
Market Cap29.87M USD
Enterprise Value18.15M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-5.86M USD
Revenue/Share—
Last Price2.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.72
EPS (TTM)-1.20 USD
EPS (Forward)—
52W Range
1.9808% of range9.500
52W High9.500 USD
52W Low1.980 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-211.56%
ROA-117.03%
ROIC—
ROCE-172.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.92M USD
CapEx (TTM)14.00K USD
FCF Margin—
FCF Yield-23.38%
Net Debt-11.71M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.04
Current Ratio8.77
Quick Ratio8.42
Book Value/Sh0.94 USD
Cash/Share1.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.50 USD
Upside (mean)+547.1%
Target Range7.000 USD – 22.00 USD
7.000+547.1% to mean22.00
# Analysts4
Ownership
Shares Out.11.71M
Float4.84M
Insiders49.15%
Institutions18.13%
Short Interest
Short Ratio3.5d
Short % Float1.08%
Short % Out.0.61%
Shares Short71.00K
Short (prev mo.)78.24K
Technical
SMA 503.310 (-23.0%)
SMA 2003.426 (-25.6%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)15.88K
Avg Vol (10d)13.20K
Technical Indicators
RSI (14)32.3
MACD-0.1945
MACD Signal-0.1650
MACD Hist.-0.0295
BB Upper3.559 USD
BB Middle2.999 USD
BB Lower2.440 USD
BB Width37.32%
ATR (14)0.2069 USD
Vol Ratio (20d)0.32x

About Nasus Pharma (NYSEAMERICAN: NSRX)

›

Nasus Pharma (NYSEAMERICAN: NSRX) is listed on NYSE American, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 7 employees.

The shares were at 2.550 USD on 19 November 2026, down 62.2% over 52 weeks. Its 52-week range is 1.980 USD to 9.500 USD: the price is 73.2% below the high and 28.8% above the low.

Its market capitalisation is 29.87M USD.

Nasus Pharma reports return on equity of -211.6% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 11.71M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.